Medical therapy is critical in preventing the worst complications of peripheral artery disease (PAD), among them heart attack ...

Beta-blocker use did not result in a lower incidence of composite death or new AMI, all-cause death, AMI, or heart failure ...

In this week’s View, Dr. Eagle looks at contemporary outcomes and trends for the transseptal mitral valve-in-valve procedure using balloon-expandable transcatheter valves. He then explores complete vs ...

In this week’s View, Dr. Eagle looks at exercise training in patients with hypertrophic cardiomyopathy (HCM). He then reviews the diagnosis and management of Kawasaki Disease. Finally, Dr. Eagle ...

There was a genetic distinction identified among development of aortic stenosis (AS) and elevated serum phosphate levels contributed to risk. The genetic correlation among coronary artery disease and ...

Disparities in health care disproportionally impact under-resourced and minority communities resulting in excess mortality and morbidity. Decreasing and eliminating these disparities will improve ...

A State-of-the-Art review published in JACC outlines the range of potential opportunities for the incorporation of artificial intelligence (AI) in the design and implementation of cardiovascular ...

Quantitative coronary plaque analysis (QCPA) is an emerging tool that allows noninvasive quantification and characterization of coronary atherosclerosis on the basis of coronary computed tomography ...

Sudden cardiac death (SCD) in obesity is the focus of a JACC: State-of-the-Art review of the mechanisms as well as current evidence for its management, gaps in knowledge and future research, published ...

American Society of Echocardiography (ASE) guidelines for echocardiographic evaluation of aortic regurgitation (AR) were found to “display very good performance” in detecting significant AR, according ...

Edoxaban was comparable to warfarin in preventing stroke or systemic embolism and intracardiac thrombus in patients with non-valvular atrial fibrillation (AFib) within three months after bioprosthetic ...

The BRAIN-AF trial failed to show that rivaroxaban prevents cognitive decline, stroke, or TIA among patients with AF. The primary outcome, cognitive decline (defined by a ≥2-point reduction in ...